FDA Clears Riverain’s Chest X-ray Software

Article

Riverain Technologies has received FDA 510(k) clearance for software aimed at improving clarity of conventional chest X-rays.

Riverain Technologies has received FDA 510(k) clearance for software aimed at improving clarity of conventional chest X-rays, the company announced.

ClearRead + Confirm also allows radiologists to confirm the proper placement of tubes, lines, and wires, the company said. Portable chest X-ray machines, typically used to confirm line and tube placement, doesn’t have high quality images, and radiologists spend time adjusting the machines to make the edges stand out.

This software increases the readability of the chest X-ray by selectively increasing contrast and suppressing the clavicles and ribs in the image, removing items that could obscure visibility of the lines and tubes.

A Georgetown University reader study assessed the time it took radiologists to locate PICC lines, nasogastric tubes, and wires that conduct or measure electrical impulses. Ten radiologists reviewed 334 X-rays with and without the software, and the software reduced the reading time by 19 percent, according to the company.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.